Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ATYR Relative to the S&P 500

ATYR Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the aTyr Pharma, Inc. (NASD:ATYR) seasonal charts above shows that a Buy Date of November 20 and a Sell Date of February 8 has resulted in a geometric average return of 1.72% above the benchmark rate of the S&P 500 Total Return Index over the past 10 years. This seasonal timeframe has shown positive results compared to the benchmark in 5 of those periods. This is a poor rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 10 years by an average of 49.53% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

To download ATYR seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ATYR